Research analysts covering 0T20.
Recent press releases and 8-K filings for 0T20.
Traws Pharma Discusses Antiviral Pipeline Progress and Q4 2024 Financials
0T20
Product Launch
Guidance Update
New Projects/Investments
- Traws Pharma presented its lead antiviral candidates, Tivoxavir Marboxil for bird flu and Ratutrelvir for COVID, highlighting their potential as best-in-class compounds.
- Tivoxavir Marboxil for bird flu has shown a broad resistance profile and efficacy in preclinical animal models, with a single dose providing protection for up to three weeks. The company anticipates FDA feedback on its Animal Rule application for rapid approval in Q2 2025.
- Ratutrelvir for COVID is a Ritonavir-independent main protease inhibitor, demonstrating significantly higher potency (EC50 of 8.4 nanomolar across 18 strains) compared to competitors like Paxlovid. This independence addresses a substantial market of high-risk patients (10-20% of Paxlovid users) who cannot take current treatments due to drug-drug interactions, and its 10-day regimen aims to prevent viral rebound and long COVID.
- As of December 31, 2024, Traws Pharma reported $21.3 million in cash and short-term investments, providing a cash runway into Q1 2026. The estimated market potential includes 300 million to 600 million doses for bird flu stockpiles and a COVID market comparable to Paxlovid's sales, which are well north of $5 billion.
Mar 31, 2025, 2:00 PM
Quarterly earnings call transcripts for 0T20.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more